SLAMF7 and AL amyloidosis: This is not to say that this is not an active area of research, however, as ADCs targeting CD46, CD48, CD74, CD138, CD307, CD319, CD352, and ASCT2 have all reached clinical trials for treatment in multiple myeloma, with varying levels of success [88].